Achilles Therapeutics is discontinuing its TIL-based cNeT program and closing its Phase I/IIa CHIRON and THETIS clinical trials The company's stock surged 31.7% in response to this announcement ...

That The Song of Achilles offers a different take on the epic story of Achilles and the Trojan War is not, ... the sea goddess Thetis — Miller's most startling creation.

– Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo ...

LONDON, Sept. 19, 2024-- Achilles Therapeutics plc today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.

Employees at Achilles Therapeutics are bracing themselves for job ... reported that it is discontinuing its TIL-based therapy programme and shutting down the phase 1/2a CHIRON and THETIS ...

Piper Sandler has downgraded Achilles (ACHL) to neutral in the wake of Phase 1/2 data from its CHIRON and THETIS studies for its precision T cell therapy. Read more here.

View TWO SPALLIERA PANELS DEPICTING THE EARLY LIFE OF ACHILLES: THETIS ENTRUSTS ACHILLES' EDUCATION TO CHIRON AND THETIS TAKES ACHILLES TO SCYROS; ACHILLES DISCOVERED AMONG THE DAUGHTERS OF LYCOMEDES ...

Shares of Achilles Therapeutics ... CHIRON and THETIS. What To Know: Achilles announced it will refocus its strategy to explore collaborations with third parties developing alternative modalities ...

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal ...